Skip to main content
Premium Trial:

Request an Annual Quote

Takeda Pharmaceutical, Rady Children's Partner on Rare Genetic Disease Drug Development

NEW YORK — Rady Children's Institute for Genomic Medicine said on Thursday that it has partnered with Japanese drugmaker Takeda Pharmaceutical to discover and develop therapies for rare child-onset genetic diseases.

Through the collaboration, RCIGM will provide Takeda with aggregated, de-identified genomic and phenotypic data derived from whole-genome sequencing performed on patients in specific disease cohorts. Takeda will use the data to discover and develop potential targeted therapeutics.

Additional terms were not disclosed.

"Rady Children's Institute for Genomic Medicine has led the way in using whole-genome sequencing to better understand the genetic drivers of rare diseases in children," Dan Curran, head of the rare genetics and hematology therapeutic area unit at Takeda, said in a statement. "It's through these efforts that we hope to derive new insights on how childhood-onset diseases manifest, enabling us to more quickly develop transformative therapies for the families who desperately need them."

In June, RCIGM — which is housed within Encinitas, California-based Rady Children's Hospital and Health Center — began working with Pacific Biosciences to explore the use of whole-genome sequencing data to diagnose rare diseases.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.